Finance

Lists
Why is 4519 down २.११%?
Dive Deeper
4519:TYO
Chugai Pharmaceutical Co Ltd
JP¥ ६,०४०.००
-२.११%
(-१३०.००) 1D
अक्टोबर १४, १५:३०:०० GMT+९  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4519...
Open
JP¥ ६,१००
High
JP¥ ६,१०६
Low
JP¥ ६,०३६
Mkt. cap
१.०१ शंख
Avg. vol.
३०.२४ लाख
Volume
२३.६० लाख
Dividend
२.२८%
Quarterly dividend
JP¥ ३४
Ex-dividend date
२०२६ जुन २९
P/E ratio
२१.०९
52-wk high
JP¥ १०,७००
52-wk low
JP¥ ५,९७४
EPS
JP¥ २८६
Shares outstanding
५४.७२ करोड
No. of employees
५ हजार
Open
JP¥ ६,१००
High
JP¥ ६,१०६
Low
JP¥ ६,०३६
Mkt. cap
१.०१ शंख
Avg. vol.
३०.२४ लाख
Volume
२३.६० लाख
Dividend
२.२८%
Quarterly dividend
JP¥ ३४
Ex-dividend date
२०२६ जुन २९
P/E ratio
२१.०९
52-wk high
JP¥ १०,७००
52-wk low
JP¥ ५,९७४
EPS
JP¥ २८६
Shares outstanding
५४.७२ करोड
No. of employees
५ हजार
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
३ घण्टा पहिले
Chugai reports vamikibart data for Chugai Pharmaceutical stock
Profile
Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO. Wikipedia
About Chugai Pharmaceutical Co Ltd
CEOOsamu Okuda
Employees५.१ हजार
Founded१९२५ मार्च १०
Headquarters-
Sector-
Next call १३ दिनमा
अक्टोबर २७, मङ्गल, ११:००
Fiscal period
Q3 2026
- / -
Revenue / Est. (JPY)
- / ३.४९ खरब
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
३.३३ खरब
३.४६ खरब
३.२२ खरब
३.४२ खरब
Cost of goods sold
१.०० खरब
८७.५६ अरब
९२.७९ अरब
१.०४ खरब
Cost of revenue
१.०० खरब
८७.५६ अरब
९२.७९ अरब
१.०४ खरब
Research and development expenses
४८.६० अरब
५२.४१ अरब
४१.८९ अरब
४७.७६ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२७.८९ अरब
३६.९२ अरब
२८.९० अरब
२९.०४ अरब
Operating expense
७६.४५ अरब
८९.७४ अरब
७०.१९ अरब
७६.५१ अरब
Total operating expenses
१.७७ खरब
१.७७ खरब
१.६३ खरब
१.८१ खरब
Operating income
१.५६ खरब
१.६९ खरब
१.५९ खरब
१.६१ खरब
Other non operating income
-३५.६० करोड
९९.४० करोड
१.४३ अरब
३.०४ अरब
EBT including unusual items
१.५६ खरब
१.७० खरब
१.६० खरब
१.६९ खरब
EBT excluding unusual items
१.५६ खरब
१.७० खरब
१.६० खरब
१.६९ खरब
Income tax expense
४४.८६ अरब
४१.५० अरब
४४.७८ अरब
५२.६९ अरब
Effective tax rate
२८.७४%
२४.४२%
२७.९५%
३१.१७%
Other operating expenses
-३.८० करोड
४०.५० करोड
-५९.६० करोड
-२९.१० करोड
Net income
१.११ खरब
१.२८ खरब
१.१५ खरब
१.१६ खरब
Net profit margin
३३.३८%
३७.०८%
३५.८७%
३४.०६%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
५.१३ अरब
Interest expense
-५.८० करोड
-९.५० करोड
-
-
Net interest expenses
-५.८० करोड
-९.५० करोड
-
५.१३ अरब
Depreciation and amortization charges
-
-
-
-
EBITDA
१.५७ खरब
२.०० खरब
१.५९ खरब
१.६२ खरब
Gain or loss from assets sale
-
४.५३ अरब
-
-
AI content may include mistakes. Learn more
Google एपहरू